Determination of (22R,S)budesonide in human plasma by automated liquid chromatography/thermospray mass spectrometry
| Autor: | Claes Lindberg, Jan Paulson, Ann Blomqvist |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Budesonide
Chromatography Elution Calibration curve Administration Topical Extraction (chemistry) Anti-Inflammatory Agents Thermospray In Vitro Techniques Mass spectrometry Biochemistry Gas Chromatography-Mass Spectrometry Acetic anhydride chemistry.chemical_compound chemistry Pregnenediones medicine Humans Molecular Medicine Glucocorticoids Quantitative analysis (chemistry) Spectroscopy medicine.drug |
| Zdroj: | Biological Mass Spectrometry. 21:525-533 |
| ISSN: | 1096-9888 1052-9306 |
| DOI: | 10.1002/bms.1200211102 |
| Popis: | (22R,S)Budesonide was isolated from human plasma by solid-phase extraction. Switching from reversed-phase conditions during sample application and washing to normal-phase conditions during elution afforded a very clean extract. Budesonide was derivatized with acetic anhydride to form the 21-acetyl derivative before analysis by reversed-phase liquid chromatography combined with thermospray mass spectrometry. Deuterium-labelled budesonide was used as internal standard. Standard samples prepared in human albumin solution were used for the calibration curve. An automated liquid chromatography/mass spectrometry system, allowing unattended overnight operation, was used for routine analysis. The recovery of budesonide from plasma was 88.9 +/- 5.9% (mean +/- SD) and the method was linear over the range 0.30-30 pmol (amount analysed), corresponding to plasma concentrations of 0.10-10 nmol l-1. Budesonide could be measured down to 0.10 nmol l-1 with a within-day variation of 10-18% (CV). The error was less than +/- 15% at 0.10 nmol l-1 and less than +/- 7% at concentrations of 0.20 nmol l-1 or higher. The total imprecision between days was 9% (CV) at a concentration of 0.30 nmol l-1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text